201 related articles for article (PubMed ID: 27609096)
1. Paeoniflorin Potentiates the Inhibitory Effects of Erlotinib in Pancreatic Cancer Cell Lines by Reducing ErbB3 Phosphorylation.
Hao J; Yang X; Ding XL; Guo LM; Zhu CH; Ji W; Zhou T; Wu XZ
Sci Rep; 2016 Sep; 6():32809. PubMed ID: 27609096
[TBL] [Abstract][Full Text] [Related]
2. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.
Frolov A; Schuller K; Tzeng CW; Cannon EE; Ku BC; Howard JH; Vickers SM; Heslin MJ; Buchsbaum DJ; Arnoletti JP
Cancer Biol Ther; 2007 Apr; 6(4):548-54. PubMed ID: 17457047
[TBL] [Abstract][Full Text] [Related]
3. ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma.
Liles JS; Arnoletti JP; Tzeng CW; Howard JH; Kossenkov AV; Kulesza P; Heslin MJ; Frolov A
Cancer Biol Ther; 2010 Sep; 10(6):555-63. PubMed ID: 20647770
[TBL] [Abstract][Full Text] [Related]
4. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway.
Zheng YT; Yang HY; Li T; Zhao B; Shao TF; Xiang XQ; Cai WM
Acta Pharmacol Sin; 2015 May; 36(5):614-26. PubMed ID: 25864651
[TBL] [Abstract][Full Text] [Related]
5. Ginsenoside Rg3 enhances the anti-proliferative activity of erlotinib in pancreatic cancer cell lines by downregulation of EGFR/PI3K/Akt signaling pathway.
Jiang J; Yuan Z; Sun Y; Bu Y; Li W; Fei Z
Biomed Pharmacother; 2017 Dec; 96():619-625. PubMed ID: 29035827
[TBL] [Abstract][Full Text] [Related]
6. Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor.
Zhang Z; Guo Y; Chen M; Chen F; Liu B; Shen C
Inflammopharmacology; 2021 Oct; 29(5):1587-1601. PubMed ID: 34322786
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer.
Ali S; Banerjee S; Ahmad A; El-Rayes BF; Philip PA; Sarkar FH
Mol Cancer Ther; 2008 Jun; 7(6):1708-19. PubMed ID: 18566242
[TBL] [Abstract][Full Text] [Related]
8. Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma.
Liles JS; Arnoletti JP; Kossenkov AV; Mikhaylina A; Frost AR; Kulesza P; Heslin MJ; Frolov A
Br J Cancer; 2011 Aug; 105(4):523-33. PubMed ID: 21792199
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line.
Lu YY; Jing DD; Xu M; Wu K; Wang XP
World J Gastroenterol; 2008 Sep; 14(35):5403-11. PubMed ID: 18803351
[TBL] [Abstract][Full Text] [Related]
10. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
11. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
12. ERBB3: Multifunctional enabler or primary actor in pancreatic cancer?
Landgraf R
Cancer Biol Ther; 2010 Sep; 10(6):564-6. PubMed ID: 20676043
[No Abstract] [Full Text] [Related]
13. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H
Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
Pino MS; Shrader M; Baker CH; Cognetti F; Xiong HQ; Abbruzzese JL; McConkey DJ
Cancer Res; 2006 Apr; 66(7):3802-12. PubMed ID: 16585207
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy.
Ali S; El-Rayes BF; Sarkar FH; Philip PA
Mol Cancer Ther; 2005 Dec; 4(12):1943-51. PubMed ID: 16373709
[TBL] [Abstract][Full Text] [Related]
16. Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway.
Yang L; Lin S; Kang Y; Xiang Y; Xu L; Li J; Dai X; Liang G; Huang X; Zhao C
J Exp Clin Cancer Res; 2019 Jan; 38(1):31. PubMed ID: 30674340
[TBL] [Abstract][Full Text] [Related]
17. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB.
El-Rayes BF; Ali S; Ali IF; Philip PA; Abbruzzese J; Sarkar FH
Cancer Res; 2006 Nov; 66(21):10553-9. PubMed ID: 17079479
[TBL] [Abstract][Full Text] [Related]
19. The retinoic acid derivative, ABPN, inhibits pancreatic cancer through induction of Nrdp1.
Byun S; Shin SH; Lee E; Lee J; Lee SY; Farrand L; Jung SK; Cho YY; Um SJ; Sin HS; Kwon YJ; Zhang C; Tsang BK; Bode AM; Lee HJ; Lee KW; Dong Z
Carcinogenesis; 2015 Dec; 36(12):1580-9. PubMed ID: 26464195
[TBL] [Abstract][Full Text] [Related]
20. Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma.
Xu L; Qi Y; Xu Y; Lian J; Wang X; Ning G; Wang W; Zhu Y
Oncotarget; 2016 Jun; 7(24):36235-36246. PubMed ID: 27105537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
